{"id":71456,"date":"2026-05-20T12:05:00","date_gmt":"2026-05-20T12:05:00","guid":{"rendered":"https:\/\/medsbase.com\/adipotide-ftpp\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"adipotide-ftpp","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/adipotide-ftpp\/","title":{"rendered":"Adipotide (FTPP \u2014 Pept\u00eddeo Pr\u00f3-Apopt\u00f3tico Direcionado a Gordura)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 Adipotide (FTPP)?<\/h3>\n<p style=\"margin: 0;\"><strong>Adipotide<\/strong> (tamb\u00e9m chamado <strong>FTPP<\/strong> \u2014 &#8220;Fat-Targeted Pro-apoptotic Peptide&#8221;) is a synthetic 25-amino-acid chimeric peptide developed by <strong>Kolonin, Arap, e Pasqualini<\/strong> no MD Anderson Cancer Center. Ele funde dois dom\u00ednios funcionalmente distintos: um pept\u00eddeo c\u00edclico de homing <strong>CKGGRAKDC<\/strong> que se liga \u00e0 prohibina-1 (e \u00e0 anexina A2) no endot\u00e9lio dos capilares do tecido adiposo branco, e um pept\u00eddeo pr\u00f3-apopt\u00f3tico \u03b1-h\u00e9lico D-estereois\u00f3mero <strong>D(KLAKLAK)<sub>2<\/sub><\/strong> que perturba as membranas mitocondriais. A quimera fundida tem como alvo seletivo a vasculatura que alimenta o tecido adiposo branco e desencadeia apoptose endotelial, privando os adip\u00f3citos de suprimento sangu\u00edneo e produzindo uma r\u00e1pida perda de massa de tecido adiposo. Publicado em macacos rhesus obesos (Barnhart et\u00a0al. 2011, <em>Science Translational Medicine<\/em>) \u2014 ~11% de perda de peso corporal em 4 semanas. <strong>Advert\u00eancia:<\/strong> documented nephrotoxicity in primate studies is the major translational limitation, and a Phase I human cancer trial (2014\u20132016) had limited published outcomes. For clinical studies use only.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Peptidomim\u00e9tico quim\u00e9rico sint\u00e9tico de 25 amino\u00e1cidos; dom\u00ednio de homing + dom\u00ednio pr\u00f3-apopt\u00f3tico unidos por ligador GG; <em>pept\u00eddeo pr\u00f3-apopt\u00f3tico direcionado a gordura<\/em><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Adipotide \/ FTPP (Pept\u00eddeo Pr\u00f3-Apopt\u00f3tico Direcionado a Gordura); sin\u00f3nimos: Pept\u00eddeo-1 direcionado \u00e0 prohibina + D(KLAKLAK)<sub>2<\/sub> quimera; CKGGRAKDC-GG-D(KLAKLAK)<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pharmaceutical-grade chimeric peptide \u2014 no single canonical CAS. Some supplier listings cite 1422956-49-3; identification primarily by published sequence (CKGGRAKDC-GG-D(KLAKLAK)<sub>2<\/sub>) em vez de CAS. Consulte o COA para identifica\u00e7\u00e3o espec\u00edfica do lote.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys (dissulfeto ciclizado Cys1\u2013Cys9, o motivo de homing de liga\u00e7\u00e3o \u00e0 prohibina \u201cCKGGRAKDC\u201d) \u2014 ligador Gly-Gly \u2014 D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys (o pept\u00eddeo \u03b1-h\u00e9lico pro-apopt\u00f3tico D(KLAKLAK)<sub>2<\/sub>). Comprimento total: 25 res\u00edduos de amino\u00e1cidos (9 + 2 + 14).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~2,611 Da (m\u00e9dia calculada; relatado como 2,500\u20132,611 Da em fontes publicadas)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pept\u00eddeo quim\u00e9rico \u2014 sequ\u00eancia CKGGRAKDC-GG-D(KLAKLAK)<sub>2<\/sub>; MF aproximado derivado da sequ\u00eancia ~C<sub>114<\/sub>H<sub>196<\/sub>N<sub>40<\/sub>O<sub>26<\/sub>S<sub>2<\/sub>; MW publicado ~2,611 Da (forma de dissulfeto c\u00edclico). Sem CAS can\u00f3nico Sigma; identifica\u00e7\u00e3o por sequ\u00eancia + COA.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mechanism<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Apoptose direcionada em duas etapas<\/strong>. (1) O dom\u00ednio de homing c\u00edclico CKGGRAKDC liga-se \u00e0 prohibina-1 \u2014 uma prote\u00edna semelhante a chaperona mitocondrial que \u00e9 expressa de forma incomum na <em>superf\u00edcie<\/em> das c\u00e9lulas endoteliais capilares que fornecem tecido adiposo branco (identificado por Kolonin et\u00a0al. 2004 em rastreio de phage-display in-vivo) \u2014 e tamb\u00e9m \u00e0 anexina A2 na mesma vasculatura. (2) Ligado \u00e0 superf\u00edcie celular, o quimera \u00e9 internalizado, e o dom\u00ednio pro-apopt\u00f3tico \u03b1-h\u00e9lico D(KLAKLAK)<sub>2<\/sub> interage diretamente com a membrana mitocondrial das c\u00e9lulas endoteliais, causando o seu colapso. Colapso mitocondrial \u2192 apoptose mediada por caspases da vasculatura adiposa \u2192 priva\u00e7\u00e3o de suprimento sangu\u00edneo dos adip\u00f3citos \u2192 perda de massa de tecido adiposo ao longo de dias a semanas.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estereoqu\u00edmica de D-Amino\u00e1cidos<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">O dom\u00ednio pro-apopt\u00f3tico KLAKLAKKLAKLAK \u00e9 sintetizado exclusivamente em <strong>Estereoqu\u00edmica de amino\u00e1cidos D<\/strong> (res\u00edduos em imagem espelhada). A estereoqu\u00edmica D confere resist\u00eancia a proteases \u2014 as proteases do hospedeiro reconhecem apenas amino\u00e1cidos L \u2014 prolongando a meia-vida in vivo do dom\u00ednio killer em rela\u00e7\u00e3o \u00e0 forma natural L. O dom\u00ednio de homing (CKGGRAKDC) est\u00e1 na estereoqu\u00edmica normal de amino\u00e1cidos L porque precisa de se ligar a uma prote\u00edna do hospedeiro (proibitina-1) na geometria can\u00f3nica recetor-ligando.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Documented Toxicity (studies-relevant)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Nefrotoxicidade<\/strong> was documented in the obese-rhesus-monkey study (Barnhart et\u00a0al. 2011) and is the leading translational limitation. The kidney expresses prohibitin and is highly vascularised, so off-target homing of the chimera to renal vasculature produces dose-dependent renal injury. The MD Anderson group repositioned the compound for cancer rather than obesity precisely because the risk-benefit balance is more favourable in a cancer-treatment context than in an elective-fat-loss context. Users in any in-vivo protocol with Adipotide should include comprehensive renal-function monitoring (BUN, creatinine, urinalysis).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder; single-use vials. Synthesis is technically demanding (D-amino-acid Fmoc-SPPS + cyclic disulfide closure of the homing domain) \u2014 purity grade matters more for this compound than for most.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC); espectrometria de massa MALDI-TOF confirma ~2,611 Da. A forma\u00e7\u00e3o da ponte dissulfuro do dom\u00ednio de homing c\u00edclico confirmada por compara\u00e7\u00e3o de massa reduzida vs n\u00e3o reduzida. COA dispon\u00edvel mediante pedido.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sol\u00favel em \u00e1gua bacteriost\u00e1tica, \u00e1gua est\u00e9ril e PBS a \u22652 mg\/mL; sol\u00favel em DMSO a \u226510 mg\/mL para prepara\u00e7\u00e3o de stock in vitro. O anfip\u00e1tico D(KLAKLAK)<sub>2<\/sub> dom\u00ednio tem propriedades semelhantes a surfactantes \u2014 as solu\u00e7\u00f5es podem apresentar espuma transit\u00f3ria na reconstitui\u00e7\u00e3o inicial; deixar assentar antes da retirada.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C n\u00e3o aberto para stock de trabalho a curto prazo; \u221220 \u00b0C para armazenamento a longo prazo (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). Aquoso reconstitu\u00eddo: 2\u20138 \u00b0C, usar dentro de ~30 dias. Proteger da luz. Evitar ciclos repetidos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o \u2014 ciclos cumulativos podem causar scrambling da ponte dissulfuro Cys1\u2013Cys9.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 Adipotide \/ FTPP?<\/h2>\n<p><strong>Adipotide<\/strong> (tamb\u00e9m chamado <strong>FTPP<\/strong> \u2014 \u201cPept\u00eddeo Pro-apopt\u00f3tico Direcionado a Gordura\u201d) \u00e9 um peptidomim\u00e9tico quim\u00e9rico sint\u00e9tico de 25 amino\u00e1cidos desenvolvido no <strong>MD Anderson Cancer Center<\/strong> por Mikhail Kolonin, Wadih Arap e Renata Pasqualini. O composto representa um dos exemplos mais claros de <strong>design racional de pept\u00eddeo quim\u00e9rico para f\u00e1rmacos<\/strong> in modern peptide pharmacology: a tissue-specific homing domain (identified by in-vivo phage display) is covalently fused to a generic killer domain (a pro-apoptotic mitochondrion-disrupting \u03b1-helical peptide), producing a chimera that delivers the killer activity selectively to the target tissue. The two functional domains and the design logic:<\/p>\n<p><strong>1. CKGGRAKDC \u2014 o p\u00e9ptido de homing que se liga \u00e0 prohibitin.<\/strong> Kolonin et\u00a0al. (2004) utilizaram a t\u00e9cnica de exibi\u00e7\u00e3o de fagos in vivo em ratos obesos para identificar um p\u00e9ptido c\u00edclico de 9 res\u00edduos (sequ\u00eancia Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys, com uma ponte dissulfeto Cys1-Cys9 que restringe a geometria) que se liga seletivamente \u00e0 vasculatura do tecido adiposo branco. O alvo de liga\u00e7\u00e3o foi posteriormente identificado como <strong>prohibitin-1<\/strong> (PHB1) \u2014 uma prote\u00edna semelhante a uma chaperona normalmente residente na membrana mitocondrial que, no endot\u00e9lio do tecido adiposo branco, tamb\u00e9m \u00e9 expressa na superf\u00edcie celular e acess\u00edvel a ligantes circulantes. A anexina A2 foi identificada como um parceiro de liga\u00e7\u00e3o secund\u00e1rio na mesma vasculatura. O dom\u00ednio de homing CKGGRAKDC \u00e9 o c\u00f3digo postal molecular que direciona a quimera especificamente para os capilares do tecido adiposo em vez do endot\u00e9lio sist\u00e9mico geral. <strong>2. D(KLAKLAK)<sub>2<\/sub> \u2014 o p\u00e9ptido killer \u03b1-h\u00e9lico pr\u00f3-apopt\u00f3tico.<\/strong> The 14-residue D-amino-acid \u03b1-helical peptide D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys is a synthetic membrane-disrupting peptide (originally developed in cancer-targeting studies by Ellerby et\u00a0al. 1999). The amphipathic \u03b1-helical geometry causes the peptide to insert into membranes; the D-amino-acid stereochemistry confers protease-resistance in vivo. Crucially, the killer activity is <em>n\u00e3o<\/em> seletiva para qualquer tipo celular espec\u00edfico \u2014 o p\u00e9ptido perturbar\u00e1 as membranas mitocondriais em praticamente qualquer c\u00e9lula em que entre \u2014 raz\u00e3o pela qual o emparelhamento com um dom\u00ednio de homing \u00e9 necess\u00e1rio para a utilidade terap\u00eautica. <strong>3. Ligador GG.<\/strong> The two functional domains are joined by a simple di-glycine linker that provides flexible spacing and avoids steric interference between the homing and killer functions. The combined chimera (CKGGRAKDC-GG-D(KLAKLAK)<sub>2<\/sub>, ~2.611 Da) foi caracterizado em macacos rhesus obesos no artigo seminal de Barnhart et\u00a0al. (2011) em <em>Science Translational Medicine<\/em> \u2014 os animais perderam aproximadamente 11% do peso corporal ao longo de 4 semanas de administra\u00e7\u00e3o di\u00e1ria por via SC, com melhorias concomitantes na sensibilidade \u00e0 insulina. No entanto, o mesmo estudo e trabalhos subsequentes documentaram <strong>nefrotoxicidade dose-dependente<\/strong>: the kidney has high prohibitin expression and is densely vascularised, so off-target homing of the chimera to renal vasculature produces renal-cortex tubular damage. The MD Anderson group repositioned Adipotide for human oncology rather than obesity, and a Phase I clinical trial in patients with metastatic prostate cancer was conducted 2014\u20132016 with limited published outcomes. The compound remains a tool today \u2014 extensively cited as a reference example of chimeric peptide drug design and the canonical pharmacological tool for studying targeted adipose-vascular apoptosis. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Apoptose Direcionada ao Tecido da Vasculatura Adiposa<\/h2>\n<p>O mecanismo do Adipotide \u00e9 um dos mais caracterizados na farmacologia de pept\u00eddeos quim\u00e9ricos:<\/p>\n<ul>\n<li><strong>Direcionamento vascular atrav\u00e9s da liga\u00e7\u00e3o \u00e0 prohibitin-1<\/strong> \u2014 O dom\u00ednio de homing CKGGRAKDC liga-se \u00e0 prohibitin-1 expressa na superf\u00edcie das c\u00e9lulas endoteliais capilares que fornecem tecido adiposo branco. A prohibitin-1 \u00e9 normalmente uma chaperona da membrana interna mitocondrial, mas no endot\u00e9lio do TAB \u00e9 expressa anomalamente no folheto externo da membrana plasm\u00e1tica, tornando-a acess\u00edvel a ligantes circulantes. O motivo CKGGRAKDC \u00e9 altamente seletivo para o pool de prohibitin do endot\u00e9lio do TAB em rela\u00e7\u00e3o a outros contextos de express\u00e3o de prohibitin \u2014 estudos de liga\u00e7\u00e3o publicados mostram um enriquecimento de ~10\u2013100 vezes do Adipotide na vasculatura do TAB em rela\u00e7\u00e3o \u00e0 vasculatura sist\u00e9mica gen\u00e9rica.<\/li>\n<li><strong>Annexina A2 como parceiro de liga\u00e7\u00e3o secund\u00e1rio<\/strong> \u2014 Trabalhos publicados subsequentes identificaram a annexina A2 como um parceiro de liga\u00e7\u00e3o adicional do dom\u00ednio de homing CKGGRAKDC no mesmo endot\u00e9lio do TAB. O padr\u00e3o de reconhecimento duplo prohibitin\/annexina A2 pode contribuir para o perfil de seletividade do Adipotide.<\/li>\n<li><strong>Internaliza\u00e7\u00e3o e entrega citos\u00f3lica do dom\u00ednio killer<\/strong> \u2014 Ap\u00f3s a liga\u00e7\u00e3o do CKGGRAKDC aos recetores da superf\u00edcie celular endotelial, o quimera \u00e9 internalizado por endocitose. O D(KLAKLAK) anfip\u00e1tico<sub>2<\/sub> o dom\u00ednio \u00e9 libertado para o citosol atrav\u00e9s da fuga endossomal e, a partir da\u00ed, acede \u00e0 membrana externa mitocondrial.<\/li>\n<li><strong>Ruptura da membrana mitocondrial e apoptose<\/strong> \u2014 A geometria anfip\u00e1tica \u03b1-h\u00e9lice de D(KLAKLAK)<sub>2<\/sub> promove a inser\u00e7\u00e3o na membrana externa mitocondrial, com subsequente despolariza\u00e7\u00e3o, liberta\u00e7\u00e3o de citocromo c e ativa\u00e7\u00e3o da cascata apopt\u00f3tica intr\u00ednseca das caspases. A estereoqu\u00edmica de amino\u00e1cidos D impede a degrada\u00e7\u00e3o proteol\u00edtica do p\u00e9ptido killer antes de atingir o seu alvo.<\/li>\n<li><strong>Abla\u00e7\u00e3o vascular \u2192 priva\u00e7\u00e3o de adip\u00f3citos \u2192 perda de massa de tecido adiposo<\/strong> \u2014 A apoptose das c\u00e9lulas endoteliais que irrigam o tecido adiposo branco (WAT) priva os adip\u00f3citos de suprimento sangu\u00edneo. Ao longo de dias a semanas, os adip\u00f3citos sofrem morte celular secund\u00e1ria por priva\u00e7\u00e3o metab\u00f3lica, e o tecido adiposo diminui. O fen\u00f3tipo macrosc\u00f3pico \u00e9 uma redu\u00e7\u00e3o de peso corporal dose-dependente, sem a mobiliza\u00e7\u00e3o lip\u00eddica aguda observada com agentes lipol\u00edticos cl\u00e1ssicos como o AOD-9604 ou agonistas \u03b23-adren\u00e9rgicos.<\/li>\n<li><strong>O problema da nefrotoxicidade<\/strong> \u2014 O rim tem uma densidade vascular muito elevada e elevada express\u00e3o de prohibitina. A homing off-target do Adipotide para os capilares renais produz danos tubulares no c\u00f3rtex renal dose-dependentes em estudos com primatas (Barnhart et al. 2011). Esta \u00e9 a principal limita\u00e7\u00e3o translacional do composto e a raz\u00e3o pela qual o programa de farmacologia da obesidade foi descontinuado em favor de aplica\u00e7\u00f5es oncol\u00f3gicas, onde um equil\u00edbrio risco-benef\u00edcio mais agressivo \u00e9 aceit\u00e1vel.<\/li>\n<\/ul>\n<p>The combined mechanistic profile makes Adipotide uniquely useful for studies on the <em>contribui\u00e7\u00e3o vascular<\/em> contribution to adipose-tissue biology \u2014 distinct from studies on adipocyte-intrinsic lipolysis (the <a href=\"https:\/\/medsbase.com\/pt-pt\/aod-9604\/\">AOD-9604<\/a> \/ \u03b23-AR) ou supress\u00e3o central do apetite mediada por GLP-1 (o eixo da fam\u00edlia <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a> \/ GLP-1 family axis). Users studying angiogenesis-vs-anti-angiogenesis approaches to obesity, or testing other targeted-apoptosis peptide constructs, use Adipotide as the canonical positive-control compound. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Adipotide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Conce\u00e7\u00e3o de f\u00e1rmacos pept\u00eddicos quim\u00e9ricos \u2014 o composto de refer\u00eancia can\u00f3nico<\/strong> \u2014 de longe o exemplo mais citado de uma quimera apopt\u00f3tica direcionada a tecidos na literatura publicada; composto de refer\u00eancia padr\u00e3o para o paradigma mais amplo de conce\u00e7\u00e3o de pept\u00eddeos terap\u00eauticos \u201cpept\u00eddeo homing + pept\u00eddeo killer\u201d<\/li>\n<li><strong>White adipose tissue vasculature studies<\/strong> \u2014 Adipotide&#8217;s WAT-vasculature selectivity makes it the canonical tool for studying the role of vascular biology in adipose tissue mass regulation; used in studies that explores whether obesity could be approached through anti-angiogenic \/ vascular-targeted strategies rather than appetite-suppressive or lipolytic strategies<\/li>\n<li><strong>Biologia da prohibina e da anexina A2<\/strong> \u2014 o trabalho de identifica\u00e7\u00e3o do recetor homing (Kolonin 2004 em diante) estabeleceu a prohibina de superf\u00edcie como um marcador vascular; o Adipotide \u00e9 a ferramenta farmacol\u00f3gica padr\u00e3o para investigar abordagens direcionadas \u00e0 prohibina em cultura endotelial prim\u00e1ria e em trabalho in vivo<\/li>\n<li><strong>Farmacologia de pept\u00eddeos pr\u00f3-apopt\u00f3ticos de amino\u00e1cidos D<\/strong> \u2014 D(KLAKLAK) \u00e9 o pept\u00eddeo D pr\u00f3-apopt\u00f3tico mais citado na literatura; o Adipotide \u00e9 a quimera mais citada que o incorpora; amplamente utilizado em investiga\u00e7\u00e3o sobre conce\u00e7\u00e3o de pept\u00eddeos resistentes a proteases<sub>2<\/sub> is the most-cited pro-apoptotic D-peptide in the literature; Adipotide is the most-cited chimera incorporating it; widely used in studies on protease-resistant peptide design<\/li>\n<li><strong>Obesity-pharmacology comparative studies<\/strong> \u2014 estudos publicados comparando diretamente Adipotide com pept\u00eddeos lipol\u00edticos (AOD-9604), agonistas do recetor GLP-1 (semaglutida, tirzepatida) e agonistas diretos do recetor \u03b23-AR (mirabegrona) caracterizam os diferentes perfis de mecanismo para redu\u00e7\u00e3o de massa adiposa<\/li>\n<li><strong>Cancer \/ tumour-vasculature studies<\/strong> \u2014 after the obesity programme was discontinued, Adipotide and related chimeras were repositioned for prostate-cancer studies (Phase I trial 2014\u20132016); published studies has explored the same homing-killer paradigm targeting tumour-specific endothelial markers (RGD-containing homing peptides + D(KLAKLAK)<sub>2<\/sub> para abla\u00e7\u00e3o da vasculatura tumoral)<\/li>\n<li><strong>Targeted apoptosis pharmacology and drug-delivery studies<\/strong> \u2014 o Adipotide \u00e9 o composto de controlo positivo can\u00f3nico para novos construtos de pept\u00eddeos de apoptose direcionados a tecidos (quimeras CPP-toxina, conjugados anticorpo-toxina com cabe\u00e7as de guerra pept\u00eddicas, etc.)<\/li>\n<li><strong>Nephrotoxicity \/ vascular off-target studies<\/strong> \u2014 the documented kidney toxicity is itself a studies subject; published work has explored the basis of the renal off-target homing and tested second-generation Adipotide analogues with modified homing domains to reduce renal accumulation<\/li>\n<\/ul>\n<p>For broader context on fat-loss and adipose-biology peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-pt\/aod-9604\/\">AOD-9604<\/a> (fragmento lipol\u00edtico exclusivo de hGH \u2014 compara\u00e7\u00e3o direta de mecanismo; direcionamento intr\u00ednseco ao adip\u00f3cito vs vascular), <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-fragment-176-191\/\">Fragmento de HGH 176-191<\/a> (o fragmento lipol\u00edtico original n\u00e3o estabilizado), <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> (agonista do recetor GLP-1 \u2014 mecanismo de supress\u00e3o central do apetite), <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a> (duplo GLP-1\/GIP \u2014 efeitos metab\u00f3licos mais amplos), e <a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a> (pept\u00eddeo metab\u00f3lico derivado de mitoc\u00f4ndrias). Explore o <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">peptides &amp; compounds catalog<\/a>, ou consulte a sele\u00e7\u00e3o <a href=\"https:\/\/medsbase.com\/pt-pt\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> hub. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Adipotide \/ FTPP in three lyophilized vial sizes calibrated to typical in-vitro and in-vivo protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Farmacologia in vitro em cultura de c\u00e9lulas e titula\u00e7\u00e3o in vivo de curta dura\u00e7\u00e3o \u2014 ensaios prim\u00e1rios de apoptose de c\u00e9lulas endoteliais vasculares adiposas, pain\u00e9is de resposta \u00e0 dose, titula\u00e7\u00e3o em coorte \u00fanica de murinos com monitoriza\u00e7\u00e3o da fun\u00e7\u00e3o renal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Concentra\u00e7\u00e3o interm\u00e9dia padr\u00e3o \u2014 protocolos in vivo em roedores com obesidade induzida por dieta (doses t\u00edpicas publicadas de 0,43 mg\/kg\/dia por via subcut\u00e2nea em ciclos de 4 semanas, conforme Kolonin 2004), tamanhos de amostra multi-coorte<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-strength vial \u2014 extended-cycle \/ multi-cohort protocols, primate-scale dosing (rhesus published doses 0.43 mg\/kg\/d), large-cohort mechanism-of-action studies; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>As tr\u00eas concentra\u00e7\u00f5es s\u00e3o a mesma entidade qu\u00edmica (Adipotide\/FTPP liofilizado, pureza \u226599% por HPLC, massa confirmada por MALDI-TOF em ~2.611 Da, dom\u00ednio de homing com dissulfeto c\u00edclico confirmado). O frasco de 10 mg oferece o menor custo por mg para protocolos in vivo em grande escala. <strong>Users conducting any in-vivo work with Adipotide should plan comprehensive renal-function monitoring (BUN, creatinine, urinalysis, histology where appropriate) from the outset, given the well-documented nephrotoxicity profile in primate studies.<\/strong> Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Como Compara \u2014 Adipotide vs AOD-9604<\/h2>\n<p>Adipotide e <a href=\"https:\/\/medsbase.com\/pt-pt\/aod-9604\/\">AOD-9604<\/a> are the two best-characterised fat-loss peptides in this catalogue, and they target adipose-tissue biology through completely different mechanisms. Adipotide acts on the <em>vasculariza\u00e7\u00e3o<\/em> que alimenta o tecido adiposo \u2014 ablando seletivamente o endot\u00e9lio do tecido adiposo branco atrav\u00e9s de apoptose direcionada, privando os adip\u00f3citos de suprimento sangu\u00edneo. O AOD-9604 atua no <em>adip\u00f3citos propriamente ditos<\/em> \u2014 driving lipolysis and suppressing lipogenesis via a \u03b23-AR-dependent mechanism (GHR-decoupled). The two compounds therefore probe completely different layers of adipose biology and are commonly used as positive controls in mechanism-of-action studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Adipotide \/ FTPP<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AOD-9604<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Classe qu\u00edmica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">pept\u00eddeo quim\u00e9rico de 25 aa (dom\u00ednio de homing + GG + pept\u00eddeo D pro-apopt\u00f3tico); dissulfeto c\u00edclico no dom\u00ednio de homing<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">pept\u00eddeo linear de 16 aa (fragmento C-terminal de hGH + Tyr N-terminal); dissulfeto interno \u00fanico<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2.611 Da<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1.815,1 Da<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Alvo celular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Endot\u00e9lio capilar do tecido adiposo branco (receptores de prohibina-1 + anexina A2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Adip\u00f3cito (receptor \u03b23-adren\u00e9rgico, hipotetizado)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Consequ\u00eancia celular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Apoptose do endot\u00e9lio vascular \u2192 inani\u00e7\u00e3o dos adip\u00f3citos \u2192 perda de massa tecidual<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ativa\u00e7\u00e3o da lip\u00f3lise (fosforila\u00e7\u00e3o da HSL) + supress\u00e3o da lipog\u00e9nese nos adip\u00f3citos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>In\u00edcio\/curso temporal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lento \u2014 dias a semanas (apoptose \u2192 cascata de inani\u00e7\u00e3o)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">R\u00e1pido \u2014 minutos a horas (ativa\u00e7\u00e3o da lip\u00f3lise)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efic\u00e1cia documentada in vivo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~11% de perda de peso corporal em 4 semanas em macacos rhesus obesos (Barnhart 2011)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ensaio de fase IIb para obesidade n\u00e3o atingiu o objetivo de perda de peso (2007)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Toxicidade documentada<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Nefrotoxicidade<\/strong> \u2014 danos tubulares no c\u00f3rtex renal dependentes da dose em estudos com primatas; grande limita\u00e7\u00e3o translacional<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Geralmente bem tolerado em ensaios cl\u00ednicos; nenhuma toxicidade org\u00e2nica espec\u00edfica documentada na Fase II<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Vascular-targeted apoptosis studies, chimeric peptide drug design, anti-angiogenic obesity studies, oncology vascular ablation<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHR-decoupled lipolysis pharmacology, structure-function HGH studies, \u03b23-AR-linked adipocyte signalling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on vascular contribution to adipose biology, chimeric peptide drug design, or targeted-apoptosis pharmacology, Adipotide is the canonical reference compound. For studies focused on direct adipocyte lipolysis isolated from GH-axis signalling, <a href=\"https:\/\/medsbase.com\/pt-pt\/aod-9604\/\">AOD-9604<\/a> is the more targeted tool. The two compounds are mechanistically complementary and are commonly used as parallel positive controls in obesity-pharmacology mechanism studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com o nosso <a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, conservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para stock de trabalho a curto prazo. Para armazenamento a longo prazo, congele frascos n\u00e3o abertos a \u221220 \u00b0C (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). O dissulfeto c\u00edclico do dom\u00ednio de homing \u00e9 est\u00e1vel no estado liofilizado. Proteja da luz. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injecte \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado). Para um frasco de 2 mg, 1,0 mL de diluente produz uma solu\u00e7\u00e3o de trabalho de 2 mg\/mL. Para um frasco de 5 mg, 1,0 mL produz 5 mg\/mL; 2,5 mL produz 2 mg\/mL. Para um frasco de 10 mg, 1,0 mL produz 10 mg\/mL (o limite pr\u00e1tico de solubilidade em tamp\u00e3o aquoso); 5,0 mL produz 2 mg\/mL. O Adipotide dissolve-se com agita\u00e7\u00e3o suave \u00e0 temperatura ambiente em 30\u201360 segundos; o anfip\u00e1tico D(KLAKLAK)<sub>2<\/sub> o dom\u00ednio pode produzir espuma transit\u00f3ria na reconstitui\u00e7\u00e3o inicial \u2014 deixe assentar antes da retirada. <strong>N\u00e3o vortex<\/strong> \u2014 high-shear mixing risks Cys1\u2013Cys9 disulfide-bond disruption of the homing domain. Once reconstituted, store the vial at 2\u20138 \u00b0C and use within 30 days. Protect from light. Avoid repeated freeze-thaw cycles of reconstituted material \u2014 cumulative cycles risk disulfide scrambling and loss of homing-domain target selectivity. Discard if cloudiness, particulates, or marked colour change appears. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>O que \u00e9 o Adipotide e como \u00e9 diferente de outros \u201cpept\u00eddeos de perda de gordura\u201d?<\/h3>\n<p>O Adipotide (FTPP) \u00e9 o exemplo can\u00f3nico de uma <strong>abordagem de apoptose direcionada vascular<\/strong> para redu\u00e7\u00e3o do tecido adiposo \u2014 completamente distinta mecanicamente dos pept\u00eddeos lipol\u00edticos (<a href=\"https:\/\/medsbase.com\/pt-pt\/aod-9604\/\">AOD-9604<\/a>, agonistas \u03b23-AR), os pept\u00eddeos de supress\u00e3o central do apetite (<a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a>, <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">tirzepatide<\/a>, a fam\u00edlia GLP-1), e os pept\u00eddeos de equil\u00edbrio energ\u00e9tico (<a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a>). Enquanto os pept\u00eddeos lipol\u00edticos ativam a mobiliza\u00e7\u00e3o lip\u00eddica intr\u00ednseca dos adip\u00f3citos, o Adipotide elimina o suprimento sangu\u00edneo <em>prevenir enjoos de movimento<\/em> the adipocytes \u2014 a fundamentally different point of mechanistic intervention. It is the canonical tool for studying the vascular contribution to adipose-tissue biology. <\/p>\n<h3>What is the documented nephrotoxicity, and what does it mean for protocols?<\/h3>\n<p>Barnhart et\u00a0al. (2011) e estudos subsequentes em primatas documentaram <strong>danos tubulares no c\u00f3rtex renal<\/strong> in Adipotide-treated rhesus monkeys. The mechanistic basis is straightforward: the kidney has very high vascular density and high prohibitin expression, so off-target homing of the chimera to renal capillaries produces the same vascular-apoptosis-then-starvation cascade as it produces in adipose tissue, but in a tissue where this is highly undesirable. This is the major translational limitation of the compound and is the reason the obesity-pharmacology programme was discontinued in favour of oncology repositioning (where a more aggressive risk-benefit balance is acceptable). Study protocols using Adipotide in vivo must include comprehensive renal-function monitoring \u2014 BUN, serum creatinine, urinalysis, and renal histology where appropriate. <\/p>\n<h3>What published dose ranges have been used in studies?<\/h3>\n<p>The Kolonin et\u00a0al. (2004) mouse work used 0.43 mg\/kg\/d SC for 4-week cycles. The Barnhart et\u00a0al. (2011) rhesus-monkey work used the same 0.43 mg\/kg\/d SC for 4 weeks, with concurrent renal-function monitoring. The Phase I human prostate-cancer trial (2014\u20132016) used escalating SC doses on a weekly or twice-weekly schedule. In-vitro endothelial-cell apoptosis assays typically use micromolar concentrations. Users should consult primary literature (Kolonin et\u00a0al. 2004, <em>Nature Medicine<\/em>; Barnhart et\u00a0al. 2011, <em>Science Translational Medicine<\/em>) para orienta\u00e7\u00f5es espec\u00edficas sobre dosagem por esp\u00e9cie, modelo e endpoint. <\/p>\n<h3>Qual \u00e9 a estereoqu\u00edmica de D-amino\u00e1cidos de D(KLAKLAK)<sub>2<\/sub>, e por que \u00e9 importante?<\/h3>\n<p>O dom\u00ednio pr\u00f3-apopt\u00f3tico killer do Adipotide \u00e9 sintetizado exclusivamente em <strong>estereoqu\u00edmica de D-amino\u00e1cidos<\/strong> \u2014 vers\u00f5es em imagem espelhada dos L-amino\u00e1cidos naturais. A raz\u00e3o \u00e9 a resist\u00eancia \u00e0s proteases: as proteases celulares e circulantes reconhecem e degradam pept\u00eddeos com base na estereoqu\u00edmica natural dos L-amino\u00e1cidos, pelo que um pept\u00eddeo de D-amino\u00e1cidos \u00e9 essencialmente invis\u00edvel \u00e0 prote\u00f3lise do hospedeiro. Isto protege o dom\u00ednio killer da degrada\u00e7\u00e3o prematura antes de atingir o seu alvo mitocondrial. O dom\u00ednio homing (CKGGRAKDC) est\u00e1 na estereoqu\u00edmica normal de L-amino\u00e1cidos porque deve ligar-se a uma prote\u00edna do hospedeiro (proibitina-1) na geometria can\u00f3nica recetor-ligando \u2014 a estereoqu\u00edmica D impediria completamente a liga\u00e7\u00e3o. Este design de estereoqu\u00edmica dividida (dom\u00ednio L para liga\u00e7\u00e3o + dom\u00ednio D para resist\u00eancia a proteases) \u00e9 um motivo recorrente no design de f\u00e1rmacos pept\u00eddicos quim\u00e9ricos e \u00e9 uma das caracter\u00edsticas mais citadas do Adipotide. <\/p>\n<h3>Por que o Adipotide n\u00e3o \u00e9 aprovado pela FDA?<\/h3>\n<p>Adipotide is a compound that completed Phase I trials in human cancer patients (prostate cancer, 2014\u20132016) but has not progressed to large-scale Phase II\/III trials. The reasons are a combination of the documented nephrotoxicity (which limits the dose window in any human-subject context), the modest published efficacy data in the limited clinical work to date, and the relatively narrow indication (vascular-targeted apoptosis is mechanism-appropriate for certain cancer settings but the broader development pathway is unclear). The compound remains a tool today, widely used as the canonical chimeric peptide drug-design reference compound. <\/p>\n<h3>Como o Adipotide \u00e9 diferente do AOD-9604?<\/h3>\n<p>Completely different mechanisms despite both being &#8220;fat-loss peptides.&#8221; <a href=\"https:\/\/medsbase.com\/pt-pt\/aod-9604\/\">AOD-9604<\/a> \u00e9 um fragmento C-terminal de 16 amino\u00e1cidos da hGH que ativa a lip\u00f3lise diretamente nos adip\u00f3citos via recetor \u03b23-adren\u00e9rgico (desacoplado do GHR). O Adipotide \u00e9 um pept\u00eddeo quim\u00e9rico de 25 amino\u00e1cidos que abla o suprimento sangu\u00edneo vascular <em>prevenir enjoos de movimento<\/em> adipocytes via targeted endothelial apoptosis. AOD-9604 produces rapid acute lipolytic effects within hours; Adipotide produces slow tissue-mass reduction over days to weeks. AOD-9604 is generally well-tolerated; Adipotide has documented nephrotoxicity. Users studying obesity mechanisms often use both as parallel positive controls representing the two ends of the &#8220;adipocyte-intrinsic vs adipose-vascular&#8221; mechanistic spectrum. <\/p>\n<h3>Can Adipotide be combined with other fat-loss peptides in protocols?<\/h3>\n<p>Sim \u2014 o Adipotide \u00e9 mecanicamente ortogonal aos p\u00e9ptidos lipol\u00edticos (<a href=\"https:\/\/medsbase.com\/pt-pt\/aod-9604\/\">AOD-9604<\/a>), aos p\u00e9ptidos do eixo GLP-1 (<a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a>, <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">tirzepatide<\/a>), e aos p\u00e9ptidos metab\u00f3licos (<a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a>), so combinations are mechanistically rational for protocols that aim to dissect different layers of adipose biology. The most-published combinations in the limited literature are Adipotide + GLP-1 agonist (testing whether vascular ablation adds to appetite-suppression-driven weight loss). Reconstitute each separately and follow each compound&#8217;s specific storage rules. As always with Adipotide in vivo, comprehensive renal-function monitoring is required regardless of the co-administered compound. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre Adipotide \/ FTPP e o \u201cp\u00e9ptido direcionado \u00e0 prohibitina-1\u201d (PTP1)?<\/h3>\n<p>O PTP1 \u00e9 apenas o p\u00e9ptido de homing \u2014 apenas a sequ\u00eancia c\u00edclica CKGGRAKDC, sem o dom\u00ednio pro-apopt\u00f3tico D(KLAKLAK)<sub>2<\/sub> dom\u00ednio killer anexado. O PTP1 sozinho liga-se \u00e0 prohibitina-1 da vasculatura do tecido adiposo branco (WAT), mas n\u00e3o desencadeia qualquer atividade apopt\u00f3tica \u2014 \u00e9 apenas o c\u00f3digo postal molecular sem a carga explosiva. O Adipotide \/ FTPP \u00e9 a quimera completa (CKGGRAKDC + ligador GG + D(KLAKLAK)<sub>2<\/sub>) that combines the homing function with the killer function. Users studying the homing-domain biology in isolation use PTP1; users studying the integrated targeted-apoptosis effect use the full Adipotide chimera. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Adipose Biology and Fat-Loss Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/aod-9604\/\"><strong>AOD-9604<\/strong><\/a> \u2014 Fragmento C-terminal lipol\u00edtico de hGH \u2014 compara\u00e7\u00e3o direta de mecanismos; direcionamento intr\u00ednseco ao adip\u00f3cito vs direcionamento vascular<\/li>\n<li><a href=\"\/pt-pt\/hgh-fragment-176-191\/\"><strong>Fragmento de HGH 176-191<\/strong><\/a> \u2014 Fragmento lipol\u00edtico n\u00e3o estabilizado \u2014 ferramenta alternativa de lip\u00f3lise direta ao adip\u00f3cito<\/li>\n<li><a href=\"\/pt-pt\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Agonista do recetor GLP-1 \u2014 mecanismo central de supress\u00e3o do apetite<\/li>\n<li><a href=\"\/pt-pt\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agonista duplo GLP-1\/GIP \u2014 efeitos metab\u00f3licos mais amplos<\/li>\n<li><a href=\"\/pt-pt\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrial-derived metabolic peptide \u2014 alternative-mechanism fat-loss studies<\/li>\n<li><a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, conservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Pept\u00eddeo quim\u00e9rico 25-aa \u2014 CKGGRAKDC homing + ligador GG + D(KLAKLAK)\u2082 pr\u00f3-apopt\u00f3tico<br \/>\n\u2705 Tem como alvo a prohibina-1 + anexina A2 no endot\u00e9lio capilar do tecido adiposo branco<br \/>\n\u2705 Desencadeia apoptose endotelial vascular \u2192 priva\u00e7\u00e3o de suprimento sangu\u00edneo aos adip\u00f3citos<br \/>\n\u2705 ~11% de perda de peso corporal em macacos rhesus ao longo de 4 semanas (Barnhart 2011, Sci Trans Med)<br \/>\n\u2705 Pept\u00eddeo quim\u00e9rico MD Anderson \/ Kolonin-Arap-Pasqualini; PM ~2.611 Da<\/p>\n<p><strong>Adipotide \/ FTPP<\/strong> contains CKGGRAKDC-GG-D(KLAKLAK)\u2082 chimeric peptide. <em>Documented nephrotoxicity in primate studies \u2014 context only.<\/em><\/p>","protected":false},"featured_media":71465,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6509,6504,6506,6502,6505,6507,6508,6494],"class_list":["post-71456","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-adipose-vasculature","product_tag-adipotide","product_tag-chimeric-peptide","product_tag-fat-loss-research","product_tag-ftpp","product_tag-pro-apoptotic-peptide","product_tag-prohibitin-targeting","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/71456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=71456"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/71465"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=71456"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=71456"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=71456"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=71456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}